• TAI-1 Hec1 Inhibitor: Advanced Workflows in Cancer Research

  2026-05-05

  TAI-1, a first-in-class Hec1 inhibitor from APExBIO, delivers robust, selective disruption of mitotic regulation for cancer research. This guide translates the latest mechanistic insights into actionable protocols and troubleshooting tips, streamlining apoptotic cell death induction across diverse cancer models.

• Patient-Derived 3D Spheroids Advance Prostate Cancer Modelin

  2026-05-05

  This study establishes and characterizes three-dimensional spheroid cultures derived from radical prostatectomy tissues as a representative translational model for organ-confined prostate cancer. The approach enables long-term culture, drug testing, and preservation, providing new avenues for mechanistic and therapeutic research.

• I-BET-762 (SKU B1498): Data-Driven Solutions for BET Inhibit

  2026-05-04

  This article guides life science researchers through real-world assay challenges using I-BET-762 (SKU B1498), a high-affinity BET inhibitor. Scenario-based Q&A blocks address experimental pitfalls, protocol optimization, and product selection, all grounded in recent literature and validated workflows. Practical recommendations help labs achieve reproducibility and mechanistic clarity in epigenetic and cancer biology research.

• A 83-01: ALK-5 Inhibitor Workflows for TGF-β Pathway Researc

  2026-05-04

  A 83-01 empowers precise TGF-β pathway inhibition, streamlining stem cell, EMT, and cancer biology assays with reproducible, data-driven outcomes. Explore experimental protocols, advanced applications, and troubleshooting strategies that set this ALK-5 inhibitor apart for applied research workflows.

• SB 202190: p38 MAP Kinase Inhibitor for Advanced Signal Diss

  2026-05-03

  SB 202190 enables precise inhibition of p38α/β MAPKs, offering unparalleled control in inflammation, apoptosis, and cancer therapeutics research. This guide translates cutting-edge findings into actionable workflows, troubleshooting tips, and advanced use-cases for maximizing assay success with SB202190 (FHPI) from APExBIO.

• Procainamide Hydrochloride: Applied Workflows in Cardiac and

  2026-05-02

  Procainamide Hydrochloride offers dual utility as a cardiac sodium channel blocker and DNMT1 inhibitor, enabling advanced arrhythmia and epigenetic assays. This guide delivers actionable workflows, protocol parameters, and troubleshooting insights drawn from both recent animal studies and best practices, positioning APExBIO's compound as a cornerstone for reproducible, translational research.

• Rotigotine Hydrochloride: Applied Workflows for Dopaminergic

  2026-05-02

  Rotigotine hydrochloride, a potent dopamine D2/D3 receptor agonist, delivers unparalleled reproducibility and neuroprotective precision in Parkinson’s disease and depression models. This article translates recent breakthroughs and expert protocols into actionable lab guidance, empowering researchers to optimize dopaminergic signaling assays and troubleshoot common experimental challenges.

• Roscovitine (Seliciclib): Selective CDK Inhibitor for Cell C

  2026-05-01

  Roscovitine (Seliciclib, CYC202) is a potent, selective inhibitor of cyclin-dependent kinases (CDKs) widely used in cancer biology research. It induces reversible cell cycle arrest in late prophase and significantly reduces tumor growth in vivo. This article provides machine-readable evidence, protocol parameters, and clarifies application limits for translational researchers.

• CLCC1 Identified as a Key Host Factor in Herpesvirus Nuclear

  2026-04-30

  This study uncovers CLCC1 as an essential host protein mediating membrane fusion during nuclear egress of herpesvirus capsids, resolving a long-standing question in herpesvirus biology. The findings offer mechanistic insight into a fundamental step of viral replication, with implications for antiviral strategy development.

• Phenothiazines Boost Macrophage Antibacterial Activity via R

  2026-04-30

  This study demonstrates that phenothiazines, including perphenazine, enhance the antibacterial function of macrophages by inducing reactive oxygen species (ROS) and autophagy. These findings highlight a host-directed therapeutic strategy that could address antibiotic resistance and improve outcomes against intracellular pathogens.

• Magnetite-Coated Cellulose Nanocrystals for Magnetic Hyperth

  2026-04-29

  This study systematically explores the self-assembly of magnetite nanoparticles on chemically tailored cellulose nanocrystals (CNCs), revealing how surface chemistry and Fe3O4 loading influence biocompatibility and magnetic heating performance. The findings provide a quantitative framework for designing safe, effective nanocomposites for biomedical hyperthermia applications.

• OSMI-1: A Benchmark O-GlcNAc Transferase Inhibitor for Resea

  2026-04-29

  OSMI-1 is a highly characterized, cell-permeable O-GlcNAc transferase inhibitor with a validated IC50 of 2.7 μM. It enables precise modulation of O-GlcNAcylation in cell and animal studies, supporting mechanistic research in ferroptosis and mitochondrial homeostasis.

• Caspase-3 Fluorometric Assay Kit: Advanced Apoptosis Quantif

  2026-04-28

  Explore the Caspase-3 Fluorometric Assay Kit for precise cysteine-dependent aspartate-directed protease activity detection. This article uniquely integrates recent mechanistic discoveries with optimized protocol guidance to elevate apoptosis research.

• Redefining mRNA Reporter Performance: Mechanisms, Metrics, M

  2026-04-28

  This thought-leadership article, authored from the perspective of APExBIO's scientific marketing leadership, unpacks the mechanistic and translational imperatives behind next-generation Firefly Luciferase mRNA systems. We integrate recent peer-reviewed LNP delivery findings and practical workflow guidance to deliver a roadmap for translational researchers seeking robust, immune-silent, and clinically relevant bioluminescent reporter outcomes. Protocol parameters, strategic insights, and a critical outlook position EZ Cap™ Firefly Luciferase mRNA (5-moUTP) as a pivotal tool for advancing gene regulation and in vivo imaging studies.

• Nose-to-Brain Rotigotine Nanoparticles for Parkinson’s Model

  2026-04-27

  This study demonstrates a novel approach to delivering Rotigotine hydrochloride via chitosan nanoparticles for direct nose-to-brain targeting in Parkinson’s disease models. The work reveals enhanced neuronal uptake, neuroprotection, and improved motor function, supporting future translational research in dopaminergic therapies.

448 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page